Login to Your Account

First Deal for Apeiron a Doozy: Getting up to $329M from GSK

By Cormac Sheridan

Thursday, February 4, 2010
Apeiron Biologics AG licensed its lead program APN01, a recombinant form of human angiotensin converting enzyme 2 (ACE2), to London-based GlaxoSmithKline plc in a deal valued at up to €236 million (US$329.4 million). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription